Kooperativer Bibliotheksverbund

UID:

Format: XII, 236 p. , online resource.

Edition: 1st ed. 2024.

ISBN: 9783031588075

Content: This book is a compendium of the worldwide ocular stem cell, gene therapy, pharmaceutical, and other miscellaneous studies treating Stargardt Disease registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study numbers and the clinical trial numbers are provided in order to make it easier for the reader to obtain further information. The book also contains an introduction to Stargardt Disease as well as analysis of the clinical trials. Clinical Trials in Stargardt Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers. .

Note: Part 1: Introduction -- Chapter 1. Introduction to Stargardt Disease -- Chapter 2. Tables -- Part 2: Recruiting Clinical Trials -- Chapter 3. United States -- Chapter 4. Spain -- Chapter 5. Switzerland -- Part 3: Enrolling by Invitation Clinical Trials -- Chapter 6. United States -- Part 4: Active, Not Recruiting -- Chapter 7. United States -- Chapter 8. Australia -- Part 5: Completed -- Chapter 9. United States -- Chapter 10. Brazil -- Chapter 11. China -- Chapter 12. Colombia -- Chapter 13. Europe -- Chapter 14. United Kingdom -- Chapter 15. No Location -- Part 6: Terminated -- Chapter 16. United States -- Chapter 17. China -- Chapter 18. Europe -- Chapter 19. Korea -- Chapter 20. United Kingdom.

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9783031588068

Additional Edition: Printed edition: ISBN 9783031588082

Additional Edition: Printed edition: ISBN 9783031588099

Language: English

DOI: 10.1007/978-3-031-58807-5

URL: https://doi.org/10.1007/978-3-031-58807-5

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (240 pages)

Edition: First edition.

ISBN: 9783031588075

Note: Includes index. , Intro -- Preface -- Contents -- Chapter 1: Introduction to Stargardt Disease -- Further Reading -- Chapter 2: Tables -- Chapter 3: Recruiting Studies -- Recruiting -- United States -- Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian) -- ClinicalTrials.gov ID NCT05956626 -- United States -- Recruiting -- Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT02402660 -- United States -- Recruiting -- Rod- and Cone-Mediated Function in Retinal Disease -- ClinicalTrials.gov ID NCT02617966 -- United States -- Recruiting -- Stargardt-Like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 -- ClinicalTrials.gov ID NCT04591483 -- United States -- Recruiting -- Oral Metformin for Treatment of ABCA4 Retinopathy -- ClinicalTrials.gov ID NCT04545736 -- United States -- Recruiting -- Genotype-Phenotype Study of Patients with Plaquenil-Induced Retinal Toxicity, with Evaluation of the ABCA4 Gene -- ClinicalTrials.gov ID NCT01145196 -- United States -- Recruiting -- Inherited Retinal Degenerative Disease Registry (MRTR) -- ClinicalTrials.gov ID NCT02435940 -- United States -- Recruiting -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Spain -- Recruiting -- Structural and Functional Characterization of Rare Ocular Diseases (RADIS) -- ClinicalTrials.gov ID NCT05258032 -- Switzerland -- Recruiting -- Function and Imaging Assessments for G1961E-associated Stargardt Disease (FIRSTORBIT) -- ClinicalTrials.gov ID NCT05674058 -- Chapter 4: Enrolling by Invitation Studies -- United States -- Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study (SUSTAIN) -- ClinicalTrials.gov ID NCT06048185 -- United States -- Enrolling by Invitation. , Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT04239625 -- Chapter 5: Active, Not Recruiting Studies -- United States -- Phase I/​II Follow-up Study of SAR422459 in Patients with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01736592 -- United States -- Active, Not Recruiting -- Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Stargardt Disease (STARLIGHT) -- ClinicalTrials.gov ID NCT05417126 -- United States -- Active, Not Recruiting -- Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects with STGD1 (DRAGON) -- ClinicalTrials.gov ID NCT05244304 -- United States -- Active, Not Recruiting -- Zimura Compared to Sham in Patients with Autosomal Recessive Stargardt Disease (STGD1) -- ClinicalTrials.gov ID NCT03364153 -- United States -- Active, Not Recruiting -- Natural History of Eye Diseases Related to ABCA4 Mutations -- ClinicalTrials.gov ID NCT01736293 -- Australia -- Active, Not Recruiting -- This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT05266014 -- Chapter 6: Completed Studies -- United States -- The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy (ProgStar-4) -- ClinicalTrials.gov ID NCT02410122 -- No Results Posted -- United States -- Completed -- Safety and Efficacy of Emixustat in Stargardt Disease (SeaSTAR) -- ClinicalTrials.gov ID NCT03772665 -- Results -- Outcome Measures -- United States -- Completed. , A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies (ProgSTAR) -- ClinicalTrials.gov ID NCT01977846 -- Results -- Outcome Measures -- United States -- Completed -- Study of STG-001 in Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT04489511 -- United States -- Completed -- DHA Supplementation in Patients With STGD3 -- ClinicalTrials.gov ID NCT00420602 -- No Results Posted -- United States -- Completed -- Pharmacodynamic Study of Emixustat Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease -- ClinicalTrials.gov ID NCT03033108 -- Results -- Outcome Measures -- United States -- Completed -- Microcurrent Stimulation to Treat Macular Degeneration -- ClinicalTrials.gov ID NCT01790958 -- United States -- Completed -- Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy -- ClinicalTrials.gov ID NCT00346853 -- United States -- Completed -- Effect of DHA Supplements on Macular Function in Patients with Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy -- ClinicalTrials.gov ID NCT00060749 -- United States -- Completed -- Long-Term Follow-Up of Subretinal Transplantation of hESC-Derived RPE Cells in Stargardt Macular Dystrophy Patients -- ClinicalTrials.gov ID NCT02445612 -- United States -- Completed -- Subretinal Transplantation of hESC-Derived RPE(MA09-hRPE)Cells in Patients with Stargardt's Macular Dystrophy -- ClinicalTrials.gov ID NCT01345006 -- Brazil -- Completed -- Stem Cell Therapy for Outer Retinal Degenerations -- ClinicalTrials.gov ID NCT02903576 -- China -- Completed -- The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients with Maculopathies -- ClinicalTrials.gov ID NCT05904444 -- Columbia -- Completed -- Efficacy of Acupuncture in Macular Diseases (AMAD) -- ClinicalTrials.gov ID NCT02255981 -- Results. , Outcome Measures -- Europe -- Completed -- Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (MADEOS) -- ClinicalTrials.gov ID NCT03297515 -- Europe -- Completed -- Pupil Dynamics and Color Vision for the Detection of Eye Diseases (PupDyn) -- ClinicalTrials.gov ID NCT04909398 -- United Kingdom -- Completed -- A Follow-Up Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT02941991 -- United Kingdom -- Completed -- Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01469832 -- No Location -- Completed -- Phase 1 Safety Study of ALK-001 in Healthy Volunteers -- ClinicalTrials.gov ID NCT02230228 -- Chapter 7: Terminated Studies -- United States -- Phase I/​IIA Study of SAR422459 in Participants with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01367444 -- Results -- Outcome Measures -- United States -- Terminated -- Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease -- ClinicalTrials.gov ID NCT01676766 -- United States -- Terminated -- Oxidative Stress in Stargardt Disease, Age-Related Macular Degeneration, and Diabetic Retinopathy -- ClinicalTrials.gov ID NCT02875704 -- Chapter 8: Unknown Status Studies -- China -- Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell-Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases -- ClinicalTrials.gov ID NCT02749734 -- Europe -- Unknown Status -- Saffron Supplementation in Stargardt's Disease (STARSAF02). , ClinicalTrials.gov ID NCT01278277 -- Europe -- Unknown Status -- Stem Cells Therapy in Degenerative Diseases of the Retina -- ClinicalTrials.gov ID NCT03772938 -- Korea -- Unknown Status -- Safety and Tolerability of MA09-hRPE Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01625559 -- United Kingdom -- Unknown Status -- Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those with Severely Reduced Vision -- ClinicalTrials.gov ID NCT04281732 -- Index.

Additional Edition: Print version: Weiss, Jeffrey N. Clinical Trials in Stargardt Disease Treatment Cham : Springer International Publishing AG,c2024 ISBN 9783031588068

Language: English